Drug Trial Radar · NCT07028281
A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors
Last checked: Nov 19, 2026Latest source record: Mar 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Jul 8, 2025
Primary completion
Dec 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 19, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-4849 injection combined with other antitumor drugs in patients with malignant solid tumors.
Conditions
- Malignant Solid Tumors
Interventions
SHR-4849、SHR-1316、SHR-8068、BP102、carboplatin、cisplatinDrug
SHR-4849、SHR-1316、SHR-8068、BP102、carboplatin、cisplatin
Primary outcomes
What the sponsor says the trial is designed to measure.
- DLT:the incidence of events associated with the investigational drug determined by the investigator during the observation period(The first stage)Time frame: up to 21 days
- Incidence and severity of AE/SAE:According to NCI-CTCAE v5.0 evaluation criteria, from the signing of informed consent to the end of safety follow-up(The first stage)Time frame: up to 24 months
- Objective Response Rate (ORR) as Assessed by investigators(The second stage)Time frame: up to 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Affiliated Cancer Hospital of Shandong First Medical University
Jinan, Shandong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.